DrugLib.com — Drug Information Portal

Rx drug information, pharmaceutical research, clinical trials, news, and more



A Study of Thymoglobulin and Tacrolimus in Liver Transplant

Information source: University of Nebraska
ClinicalTrials.gov processed this data on August 23, 2015
Link to the current ClinicalTrials.gov record.

Condition(s) targeted: Liver Transplantation; Liver Disease; Immunosuppression

Intervention: anti-thymocyte globulin (rabbit) (Drug); tacrolimus (Drug)

Phase: Phase 4

Status: Enrolling by invitation

Sponsored by: University of Nebraska

Official(s) and/or principal investigator(s):
Wendy Grant, MD, Principal Investigator, Affiliation: University of Nebraska

Summary

The purpose of this study is to compare kidney function, long term patient and graft survival, and incidence of acute rejection in liver transplant recipients between one group receiving thymoglobulin induction and delayed initiation of tacrolimus and another group of liver transplant recipients having immediate administration of tacrolimus without any induction immunosuppression.

Clinical Details

Official title: A Study Comparing Thymoglobulin to Tacrolimus in Liver Transplant and Impact on Renal Function

Study design: Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment

Primary outcome: Evaluation of renal function via Glo-Fil nuclear medicine scan and laboratory parameters

Secondary outcome: patient and graft survival, incidence of acute rejection, incidence of active CMV disease, incidence of other infections, any adverse events or serious adverse events associated with the use of thymo induction therapy

Detailed description: Renal insufficiency following liver transplantation in adult recipients is a major cause of morbidity and a major contributor to mortality. One of the key factors contributing to this renal dysfunction is the use of calcineurin inhibitors. There is some evidence to suggest that the first 7-10 days following liver transplantation are crucial in terms of renal function and the ability to avoid the use of nephrotoxic agents such as calcineurin inhibitors may have a significant impact on long-term outcome.

Eligibility

Minimum age: 19 Years. Maximum age: N/A. Gender(s): Both.

Criteria:

Inclusion Criteria:

- Primary liver transplant recipient with Model for End Stage Liver Disease (MELD)

criteria documentation

- Over 18 years of age

- Signed informed consent form

- if female of childbearing potential: Must not be lactating Must have negative serum

pregnancy test on study day 0 Must have agreed on a reliable and acceptable form of contraception during the study

- sexually active males must be practicing an acceptable form of contraception

Exclusion Criteria:

- Multiple organ transplants

- Prior solid organ or bone marrow transplant recipients

- Fulminant hepatic failure

- Status 1 transplants

- Liver transplant candidates with greater than 6 weeks of dialysis

- Patients who in the opinion of the Investigator are not eligible for thymo induction

at the time of transplant

- Recipients of investigational therapy within 90 days prior to transplant

- Know contraindication to administration of rabbit anti-thymocyte globulin

- Patients whose medical condition is such that the physician feels it would not be in

their best interest to participate in the study

- Patients who are unwilling to have a Glofil nuclear medicine scan at specified time

points

- History of malignancy within 5 years with the exception of:

- Adequately treated localized squamous or basal cell carcinoma of the skin without

evidence of recurrence, and /or

- Hepatocellular carcinoma

Locations and Contacts

University of Nebraska Medical Center, Omaha, Nebraska 68198, United States
Additional Information

Related publications:

1. Fisher NC, Nightingale PG, Gunson BK, Lipkin GW, JM. N. Chronic renal failure following liver transplantation: a retrospective analysis Transplantation 1998; 66 (1): 59. 2. Gonwa TA, Mai ML, Melton LB, et al. End-stage renal disease (ESRD) after orthotopic lvier transplantation (OLTX) using calcineurin-based immunotherapy. Transplantation 2001; 72: 1934. 3. Moreno JM, Cuervas-Mons V, Rubio E, et al. Chronic renal dysfunction after liver transplantation in adult patients: prevelance, risk factors, and impact on mortality. Transplant Proc 2003; 35 (5): 1907.

Starting date: December 2007
Last updated: November 27, 2007

Page last updated: August 23, 2015

-- advertisement -- The American Red Cross
 
Home | About Us | Contact Us | Site usage policy | Privacy policy

All Rights reserved - Copyright DrugLib.com, 2006-2017